Clinical trial NCT03913130: Extension Study to Study PQ-110-001 (NCT03140969)
Official title: An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Leber Congenital Amaurosis 10
Blindness
Leber Congenital Amaurosis
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Eye Diseases
Eye Diseases, Hereditary
Eye Disorders Congenital
Retinal Disease
Keywords: LCA10
CEP290
p.Cys998X
c.2991+1655A>G
Leber's Congenital Amaurosis
Antisense oligonucleotide
RNA therapy
Lead sponsor: Laboratoires Thea
Sponsor class: INDUSTRY
Collaborators: name: Sepul Bio
First posted: 2019-04-12
Enrollment: 9
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.

Detailed description: Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject.

Subjects will be given the opportunity to enroll into this extension study for continued dosing if available data support current and/or future benefits for the subject. The Investigator, in consultation and agreement with the Medical Monitor, will decide on enrollment of each individual subject, as well as on dosing of the first treated eye and treatment initiation of the contralateral eye. Continued subject treatment in this study is desirable, but cannot be guaranteed, since it will depend on the risks and benefit of further treatment on a case-by-case basis, as discussed and agreed upon with the Medical Monitor.

The contralateral eye and the first treated eye will be injected 3 months apart. The injection interval of 3 months between both eyes will limit burden for the subjects, with a 3 month-visit frequency during the course of the study. This between-eye interval could be adapted if safety data are supportive, and for logistic reasons, and in agreement with the Medical Monitor.

The same safety monitoring protocol and efficacy assessments will apply to both eyes.

QR-110 will be administered via intravitreal (IVT) injection.

Eligibility criteria: Inclusion Criteria:

* Subjects who completed participation in the study PQ-110-001 and who may derive benefit from continued treatment with QR 110, as assessed by the Investigator, in consultation with the Medical Monitor
* Persistence of detectable outer nuclear layer (ONL) in the area of the macula in the opinion of the Investigator, as determined by OCT.
* Clear ocular media and adequate pupillary dilation to permit good quality retinal imaging, as assessed by the Investigator.
* An adult (≥ 18 years) willing and able to provide informed consent for participation OR a minor (6 to \< 18 years) with a parent or legal guardian willing and able to provide written permission for the subject's participation prior to performing any study related procedures, and pediatric subjects able to provide age-appropriate assent for study participation.
* Female subjects who have reached menarche and male subjects must either practice true abstinence in accordance with their preferred and usual lifestyle, or agree to use acceptable, highly effective methods of contraception for up to 3 months following their last dose QR-110. Acceptable methods of contraception are defined in the protocol. Women of non-childbearing potential may be included without the use of adequate birth control, provided they meet the criteria in the protocol.

Exclusion Criteria:

* Any contraindication to IVT injection according to the Investigator's clinical judgment and international guidelines (Avery 2014).
* Safety issue during study PQ-110-001 that may compromise subject safety when continued dosing, as determined by the Investigator, and in consultation with the Medical Monitor.
* Any ocular or systemic disease or condition (including medications and laboratory test abnormalities) that could compromise subject safety or interfere with assessment of efficacy and safety, as determined by the Investigator and in consultation with the Medical Monitor.
* Pregnant or breast-feeding female.

Primary outcomes:
measure: Frequency of Ocular AEs
timeFrame: 24 months
measure: Frequency of Non-ocular AEs
timeFrame: 24 months
Secondary outcomes:
measure: Change in BCVA in First Treated Eye
timeFrame: 24 months
measure: Change in Mobility Course Score
timeFrame: 24 months
measure: Change in Photoreceptor Outer Segment Layer Thickness
timeFrame: 24 months
measure: Change in OCI
timeFrame: 24 months
measure: Change in FST Blue
timeFrame: 24 months
measure: Change in FST Red
timeFrame: 24 months
measure: Change in VFQ-25
timeFrame: 24 months
measure: Change in CVAQ
timeFrame: 24 months
measure: Change in PLR
timeFrame: 24 months
measure: Change in NIRAF
timeFrame: 24 months
measure: Change in BCVA in Treated Contralateral Eye
timeFrame: 24 months
measure: Change in BCVA in Non-Treated Contralateral Eye
timeFrame: 24 months
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
city: Philadelphia
country: United States
facility: Scheie Eye Institute, University of Pennsylvania
state: Pennsylvania
city: Ghent
country: Belgium
facility: Ghent University Hospital and Ghent University
Study officials:
affiliation: Sepul Bio
name: Sepul Bio Chief Medical Officer
role: STUDY_DIRECTOR
References: